Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize
Conditions Studied
Interventions
- BIOLOGICAL Empasiprubart IV
- OTHER Placebo IV
Study Locations (19)
Other
- Peking University First Hospital - Changqiao Campus — Beijing
- Nanfang Hospital Southern Medical University — Guangzhou
- High Technology Hospital MedCenter Ltd — Batumi
- First Medical Clinic LLC — Batumi
- Petre Sarajishvili Institute of Neurology — Tbilisi
- Aleksandre Aladashvili Clinic — Tbilisi
- Curatio JSC — Tbilisi
- LTD New Hospitals — Tbilisi
- Geo Hospitals — Tbilisi
- Jo Ann Medical Center — Tbilisi
- Southern TOHOKU Medical Clinic — Kōriyama
- Seoul National University Hospital — Seoul
- Korea University Guro Hospital — Seoul
Texas
- National Neuromuscular Research Institute — Austin
- NeuroCarePlus — Houston
Colorado
- Colorado Springs Neurological Associates — Colorado Springs
District of Columbia
- Medstar Health Research Institute — Washington D.C.
Florida
- Gables Neurology — Miami
Louisiana
- Paradigm Health System — Slidell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2031-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07091630
The ClinicalTrials.gov registry entry for NCT07091630 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 96 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 2 interventions — of which Empasiprubart IV is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07091630 reports 19 study locations spanning 6 distinct geographic areas — top geographies include Other, Texas, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07091630 about?
NCT07091630 is a clinical study titled "A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP". The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all partici...
What is the current status of trial NCT07091630?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2025-09-16. Estimated completion is 2031-01-23.
What conditions does trial NCT07091630 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07091630?
The interventions under investigation include: Empasiprubart IV (BIOLOGICAL), Placebo IV (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07091630?
This trial is sponsored by argenx, which has 96 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07091630 being conducted?
This trial has 19 study locations across Colorado, District of Columbia, Florida, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.